Bleeding Response in Hemophilia

Written by Margaret Anne Rockwood | Last updated August 7th, 2026
Medically reviewed by Shannon Walker, MD

Hemophilia A and hemophilia B are inherited bleeding disorders resulting from deficiency or dysfunction of factor VIII (FVIII) and factor IX (FIX), respectively. Although traditionally described as coagulation factor deficiencies, contemporary understanding recognizes hemophilia as a disorder of impaired thrombin generation caused by disruption of the intrinsic tenase complex.

The central pathophysiologic defect is not failure of clot initiation but failure of coagulation amplification. This distinction explains the characteristic bleeding phenotype of hemophilia and provides the biologic rationale for modern therapeutic approaches, including factor replacement, non-factor therapies, and gene-transfer strategies.

Normal Hemostasis

Hemostasis is a coordinated series of vascular, cellular, and enzymatic events that limit blood loss while preserving vascular patency. Following vascular injury, vasoconstriction reduces blood flow, platelets adhere to exposed subendothelial collagen through von Willebrand factor, and a temporary platelet plug forms. Simultaneously, exposure of tissue factor initiates coagulation through activation of factor VII, producing small amounts of thrombin.

This initiation phase is only the beginning of effective clot formation. Durable hemostasis requires amplification of thrombin generation through activation of factors VIII and IX within the intrinsic pathway. Without this amplification, the initial platelet plug cannot mature into a mechanically stable fibrin clot.

Rather than functioning as two independent coagulation pathways, the extrinsic and intrinsic systems operate sequentially. The extrinsic tissue factor pathway initiates coagulation, while the intrinsic pathway generates the thrombin burst required for stable clot formation.

The Intrinsic Tenase Complex

The defining molecular abnormality in hemophilia lies within the intrinsic tenase complex. In normal physiology, factor VIII functions as a cofactor, while factor IX serves as a vitamin K-dependent serine protease. Following activation by thrombin, activated factor VIII (FVIIIa) dissociates from von Willebrand factor and assembles with activated factor IX (FIXa) on activated platelet membranes to form the intrinsic tenase complex.

This complex is one of the most efficient enzymatic systems in human physiology. In normal physiology, intrinsic tenase is able to localize FIXa on phospholipid surfaces, dramatically accelerating activation of factor X by several orders of magnitude compared with FIXa alone.

Then, that amplified factor X enters the common pathway. Together with factor Va, factor Xa forms the prothrombinase complex. This generates thrombin, which converts fibrinogen to fibrin. The prothrombin complex also activates platelets and multiple upstream coagulation factors through positive feedback loops.

The resulting thrombin burst transforms a temporary platelet plug into a durable fibrin clot capable of withstanding normal blood flow and tissue movement.

Where Coagulation Fails

In hemophilia, the extrinsic tissue factor-factor VIIa pathway remains intact and generates the small amount of thrombin necessary to initiate coagulation. Platelet adhesion, activation, and aggregation therefore occur normally.

The defect emerges during the amplification phase of the intrinsic pathway. FVIII and FIX are central to amplification because FIXa is the enzyme and FVIIIa is its cofactor within the intrinsic tenase complex. Together, they assemble on activated platelet phospholipid surfaces and accelerate conversion of factor X to factor Xa far more efficiently than FIXa alone. Loss of either component sharply reduces factor Xa generation, limiting prothrombinase activity and preventing the thrombin burst required for stable fibrin formation.

Even modest reductions in FVIII or FIX activity have profound effects on thrombin generation. Deficiency of either factor VIII or factor IX markedly reduces intrinsic tenase activity, impairing activation of factor X and preventing adequate thrombin amplification. Although coagulation begins normally, too little thrombin is produced to generate a stable fibrin network.

The clinical consequence is an unstable clot that initially appears effective but subsequently breaks down under physiologic stress.

In short, hemophilia is fundamentally a failure to sustain coagulation rather than a failure to initiate it.

Why Bleeding Is Delayed

The characteristic bleeding pattern in hemophilia follows directly from this molecular defect.

Patients frequently achieve apparently successful hemostasis immediately after injury because platelet function and early coagulation remain intact. Hours later, however, inadequate thrombin generation prevents sufficient fibrin deposition and factor XIII-mediated cross-linking. As blood flow and tissue movement place mechanical stress on the immature clot, it destabilizes, and bleeding recurs.

This mechanism explains several familiar clinical observations:

• delayed bleeding after trauma
• recurrent hemorrhage following initially successful hemostasis
• prolonged postoperative bleeding
• large soft tissue hematomas

These manifestations distinguish hemophilia from disorders of primary hemostasis, in which bleeding begins immediately because platelet function is impaired.

Disease Severity: A Look at Factors VIII and IX

Although factor VIII and factor IX function together within the intrinsic tenase complex, they differ substantially in their biology.

Factor VIII is a large glycoprotein synthesized primarily by endothelial cells — particularly liver sinusoidal endothelial cells — rather than hepatocytes. It circulates bound to von Willebrand factor, which protects it from premature degradation until activation by thrombin.

Factor IX is synthesized in the liver as a vitamin K-dependent coagulation factor. Once activated, FIXa binds FVIIIa on activated platelet membranes, where the two proteins function cooperatively to accelerate factor X activation.

Loss of either protein disrupts the same amplification step, explaining why hemophilia A and hemophilia B produce nearly identical clinical phenotypes despite involving different coagulation factors.

Disease severity generally correlates with residual clotting factor activity. Patients with severe disease (<1% factor activity) frequently experience spontaneous hemarthroses and deep muscle hemorrhage. Moderate disease (1% to 5% activity) is associated with bleeding after minor trauma, while patients with mild disease (>5% to 40% activity) often remain undiagnosed until surgery or significant injury reveals the underlying defect.

Residual factor activity, however, does not entirely determine bleeding phenotype. Physical activity, treatment history, modifier genes, environmental factors, and individual variation in thrombin generation all contribute to clinical severity.

A clear understanding of these molecular mechanisms provides the biologic foundation for interpreting disease manifestations and understanding how the new treatments work and how consequential they are for patients with this disorder.

Sources

• Basavaraj MG, et al. Exosite binding drives substrate affinity for the activation of factor X by the intrinsic Xase complex. J Biol Chem. 2020.
• Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001.
• Hoffman M, Monroe DM. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003.
• Hultin MB. Activation of human factor X by factors IXa and VIII. J Clin Invest. 1978.
• Kiouptsi K, et al. Physiological roles of the von Willebrand factor–factor VIII interaction. J Thromb Haemost. 2020.
• Panteleev MA, et al. Kinetics of factor X activation by the membrane-bound complex of factor IXa and factor VIIIa. Biochem J. 2004.
• Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost. 2006.
• Severeid PE, et al. Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells. Blood Adv. 2026.
• Sidonio RF Jr, et al. Thrombin generation and implications for hemophilia therapies. Res Pract Thromb Haemost. 2022.
• Smith SA, et al. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio). 2009.
• Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
• Swieringa F, et al. Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow. Haematologica. 2015.
• Terraube V, O’Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010.
• Turner NA, Moake JL. Factor VIII is synthesized in human endothelial cells, packaged in Weibel-Palade bodies and secreted bound to ULVWF strings. PLoS One. 2015;10(10):e0140740. doi:10.1371/journal.pone.0140740.
• Wolberg AS. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008.